Log in

Relevant bibliographies by topics / Patient data. combined medium for autologous / Journal articles

To see the other types of publications on this topic, follow the link: Patient data. combined medium for autologous.

Journal articles on the topic 'Patient data. combined medium for autologous'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Patient data. combined medium for autologous.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Anders, Sven, Martin Volz, Hubert Frick, and Jörg Gellissen. "A Randomized, Controlled Trial Comparing Autologous Matrix-Induced Chondrogenesis (AMIC®) to Microfracture: Analysis of 1- and 2-Year Follow-Up Data of 2 Centers." Open Orthopaedics Journal 7, no. 1 (2013): 133–43. http://dx.doi.org/10.2174/1874325001307010133.

Full text

Abstract:

Microfracture (MFx) is currently the recommended option for the treatment of small cartilage defects but is not regarded as suitable for the treatment of defects larger than 2.5 cm2. To extent its applicability to medium-sized defects MFx has been combined with a collagen type I/III matrix (Chondro-Gide®). This technique is called Autologous Matrix-Induced Chondrogenesis (AMIC®) and meanwhile a clinically established treatment option for localized full-thickness small- to medium-sized cartilage defects. Despite its more spreading clinical use, clinical data published so far are limited to main

APA, Harvard, Vancouver, ISO, and other styles

2

Ganesan, Saravanan, Ezhilarasi Chendamarai, Jayandharan G. Rao, et al. "Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data." Blood 118, no. 21 (2011): 947. http://dx.doi.org/10.1182/blood.v118.21.947.947.

Full text

Abstract:

Abstract Abstract 947 About 5–10% newly diagnosed and about 20–30% of relapsed acute promyelocytic leukaemia (APL) patients will have disease recurrence after receiving currently accepted standards of care. There are a limited number of drugs in the armamentarium for treatment of APL. Preliminary work from our laboratory suggests that stromal cell adhesion mediated drug resistance (CAM-DR) is probably significant with arsenic trioxide (ATO) and is seen both in APL cell lines (n=8; figure 1A) and primary APL cells (n=26; data not shown). Preliminary data suggests that bortezomib (Bo) has cytoto

APA, Harvard, Vancouver, ISO, and other styles

3

Liu, Yu, Li Wang, Haocheng Yu, Samir S. Parekh, Eric Schadt, and Jun Zhu. "ISS stage and network risk score to predict benefits of multiple myeloma treatment options." Journal of Clinical Oncology 38, no. 15_suppl (2020): e20511-e20511. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20511.

Full text

Abstract:

e20511 Background: Multiple myeloma (MM) is molecularly heterogeneous with many treatment regimens developed targeting different aspects of the disease. Multi-omics studies are now widely available, facilitating a precision medicine approach for personalized MM treatments. However, data from these studies vary with respect to treatment regimens, patient age, disease stage, and genomic alterations, thus complicating identification of treatment effects. Methods: From a Multiple Myeloma Molecular Causal Network (M3CN) model we previously described, we identified a prognostic subnetwork (prognNET)

APA, Harvard, Vancouver, ISO, and other styles

4

Golay, Josée, Anna D’amico, Gianmaria Borleri, et al. "Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients." Blood 122, no. 21 (2013): 3272. http://dx.doi.org/10.1182/blood.v122.21.3272.3272.

Full text

Abstract:

Abstract Background The combined use of chemotherapy and monoclonal antibodies has proved highly effective for the treatment of CLL but often results in severe life threatening immunosuppression. The development of adoptive therapy with autologous T cells could be clinically relevant to overcome these problems. Methods We have devised a novel, simple and efficient method for ex vivo expansion of normal autologous T cells from the peripheral blood of CLL patients for adoptive therapy, using blinatumomab (CD3xCD19) and rhIL-2 in serum-free medium. The complete phenotype of in vitro expanded T ce

APA, Harvard, Vancouver, ISO, and other styles

5

Aparicio-Soto, Marina, Caterina Curato, Franziska Riedel, Hermann-Josef Thierse, Andreas Luch, and Katherina Siewert. "In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals—A Systematic Review." Cells 11, no. 1 (2021): 83. http://dx.doi.org/10.3390/cells11010083.

Full text

Abstract:

Background: Chemical allergies are T cell-mediated diseases that often manifest in the skin as allergic contact dermatitis (ACD). To prevent ACD on a public health scale and avoid elicitation reactions at the individual patient level, predictive and diagnostic tests, respectively, are indispensable. Currently, there is no validated in vitro T cell assay available. The main bottlenecks concern the inefficient generation of T cell epitopes and the detection of rare antigen-specific T cells. Methods: Here, we systematically review original experimental research papers describing T cell activation

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Jing, and Bao-An Chen. "Traditional Chinese Medicine Is Used to the Maintenance Therapy of Diffuse Large B Cell Lymphoma." Blood 134, Supplement_1 (2019): 5316. http://dx.doi.org/10.1182/blood-2019-126604.

Full text

Abstract:

Background: Diffuse large B cell lymphoma (DLBCL) is one of the most common malignancy hematologic disease in China. At present, the NCCN recommended first-line therapy to DLBCL is: rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) or etoposide, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-EPOCH). For the medium-risk and high-risk adult patients, autologous hematopoietic stem cell transplantation (auto-HSCT) is recommended as consolidation therapy. However, no maintenance therapy is recommended. A number of clinical trials of rituximab or

APA, Harvard, Vancouver, ISO, and other styles

7

Quach, Hang, Daniel North, Susanna Freddi, Shuh Y. Tan, Lenny Straszkowski, and Harshal Nandurkar. "High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma." Blood 126, no. 23 (2015): 4206. http://dx.doi.org/10.1182/blood.v126.23.4206.4206.

Full text

Abstract:

Abstract Background: GRP78 (78-kDa glucose-regulated protein) is a molecular chaperone that is upregulated during cellular stress. It has been well demonstrated that GRP78 upregulation is associated with chemoresistance and metastasis in solid tumours. GRP78 has not been widely explored in multiple myeloma (MM), however, we and others have shown that GRP78 is much more overexpressed in myeloma cell lines compared to other cell lines. To assess the clinical relevance of GRP78 overexpression in MM, we investigated the association of plasma cell GRP78 expression on primary bone marrow (BM) trephi

APA, Harvard, Vancouver, ISO, and other styles

8

Xiao, Juan, Bing Han, Wanling Sun, Yuping Zhong, and Yongji Wu. "Ex Vivo Expansion and Long-Term Hematopoietic Reconstitution Ability of Sorted CD34+CD59+ Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria." Blood 112, no. 11 (2008): 2324. http://dx.doi.org/10.1182/blood.v112.11.2324.2324.

Full text

Abstract:

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder characterized by intravascular hemolysis, venous thrombosis, and bone marrow (BM) failure. Until now, allogeneic hematopoietic stem cell transplantation is still the only way to cure PNH. Eculizumab, although very promising, is not the eradication of the disease because of raising the possibility of severe intravascular hemolysis if therapy is interrupted. Here we enriched the residual bone marrow normal progenitor cells (marked by CD34+CD59+) from PNH patients, tried to find an effective way of exp

APA, Harvard, Vancouver, ISO, and other styles

9

Naumann, A., N. Rotter, J. Bujía, and J. Aigner. "Tissue Engineering of Autologous Cartilage Transplants for Rhinology." American Journal of Rhinology 12, no. 1 (1998): 59–64. http://dx.doi.org/10.2500/105065898782102972.

Full text

Abstract:

In reconstructive surgery there is increasing demand for cartilage transplants to fill defects, especially nose and/or outer ear defects. Tissue engineering is one of the most modern pathways to generate autologous cartilage transplants. Isolated chondrocytes obtained from a tiny patient's biopsy were seeded on bioresorbable preshaped cell carriers to provide a 3-dimensional cell arrangement as in vivo. The combined use of these cell carriers in form of a non-woven mesh and a constant medium perfusion was performed to generate a cartilage-like cell-polymer-construct, which was finally subcutan

APA, Harvard, Vancouver, ISO, and other styles

10

Pilco Pilco, Rocio Matilde, Eduardo Rene Arias Salazar, Juan Sebastian Ordóñez Lasso, et al. "Functional and aesthetic outcomes of combined reconstructive tchniques in complex abdominal surgery." Ibero-American Journal of Health Science Research 4, no. 2 (2024): 64–71. http://dx.doi.org/10.56183/iberojhr.v4i2.643.

Full text

Abstract:

Background: Complex abdominal surgeries, necessitated by severe conditions like cancer, trauma, and inflammatory diseases, require advanced expertise and precise, multifaceted techniques to restore function and appearance. This review systematically assesses the outcomes of combined reconstructive techniques, such as mesh reinforcement, component separation, flap reconstruction, and laparoscopic-assisted repairs, in achieving optimal functional and aesthetic results. Methodology: RCTs, cohort studies, and case series on reconstructive techniques in complex abdominal surgeries for adults were i

APA, Harvard, Vancouver, ISO, and other styles

11

Anichini, A., C. Maccalli, R. Mortarini, et al. "Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients." Journal of Experimental Medicine 177, no. 4 (1993): 989–98. http://dx.doi.org/10.1084/jem.177.4.989.

Full text

Abstract:

HLA-A2-restricted, CD3+, CD8+, alpha/beta+ cytotoxic T cell (CTL) clones were isolated from peripheral blood (PBL) or tumor infiltrating lymphocytes (TIL) of two HLA-A2+ melanoma patients (9742 and 5810), to evaluate the possible recognition of autologous melanoma and of allogeneic HLA-A2-matched normal melanocytes. These CTL clones lysed not only fresh and cultured autologous melanoma cells, but also allogeneic HLA-A2+, but not HLA-A2-, normal melanocytes. The lysis of autologous neoplastic cells and of melanocytes could be inhibited by an anti-HLA-A2 monoclonal antibody (mAb). Lysis of the n

APA, Harvard, Vancouver, ISO, and other styles

12

Costa-Paz, Matias, Juan Pablo Zicaro, and Carlos Yacuzzi. "Autologous Collagen-Induced Chondrogenesis Technique for Knee Chondral Lesions." Orthopaedic Journal of Sports Medicine 5, no. 1_suppl (2017): 2325967117S0002. http://dx.doi.org/10.1177/2325967117s00028.

Full text

Abstract:

Objectives: The purpose of the study was to evaluate a series of patients with osteochondral lesions who underwent a microfractures treatment and autologous collagen-induced chondrogenesis technique (ACIC). Methods: Microfracture treatment and ACIC was performed in eight patients with grade IV cartilage lesion of more than 3 cm2 long. Two patients were discarded due to short follow-up. Four women and two men were evaluated with 50 year-old mean age. The average follow-up was 12.5 months. An associated valgus osteotomy was performed in two patients. Patients were evaluated using the Lysholm sco

APA, Harvard, Vancouver, ISO, and other styles

13

Vollbach, Felix H., Benjamin F. Thomas, and Hisham Fansa. "Identification of Independent Risk Factors for Skin Complications in a Multifactorial Logistic Regression Analysis of Simultaneous Immediate Autologous Breast Reconstruction and Skin Reduction Mastectomy in Large and Ptotic Breasts Using an Inferiorly Based Deepithelialized Dermal Breast Flap." Journal of Personalized Medicine 12, no. 3 (2022): 332. http://dx.doi.org/10.3390/jpm12030332.

Full text

Abstract:

Autologous immediate breast reconstruction in large and ptotic breasts remains challenging. We aimed to identify independent risk factors for impaired wound healing and nipple necrosis after skin reducing wise pattern mastectomy in autologous reconstruction with an auxiliary deepithelialized inferiorly based dermal flap (IBDF). Methods. This retrospective study examined patients with wise pattern mastectomy with autologous immediate breast reconstruction (IBR) between 2017 and 2019. All cases of large and ptotic breasts were included. Demographic, oncologic, reconstructive, and surgical data w

APA, Harvard, Vancouver, ISO, and other styles

14

Galligioni, Enzo, Manuela Santarosa, Daniela Favaro, Antonella Spada, Renato Talamini, and Michele Quaia. "In Vitro Synergic Effect of Interferon Gamma Combined with Liposomes Containing Muramyl Tripeptide on Human Monocyte Cytotoxicity Against Fresh Allogeneic and Autologous Tumor Cells." Tumori Journal 80, no. 5 (1994): 385–91. http://dx.doi.org/10.1177/030089169408000514.

Full text

Abstract:

Aims The purpose of the present study was to investigate whether human recombinant interferon- γ (hrIFN - γ) can act synergically with various activators in increasing the cytotoxicity of cancer patient monocytes against fresh autologous and allogeneic tumor cells. Methods Fresh target cells were obtained by means on the mechanical and enzymatic dissociation of human renal carcinomas. A 375 and SW 626 cell lines were used as positive controls. Monocytes from renal cancer patients and normal volunteers were activated in vitro with lipopolysaccharide, muramyl tripeptide (MTP-PE) or liposomes con

APA, Harvard, Vancouver, ISO, and other styles

15

Garcia, Heidy lyz. "Peripheral Blood Progenitor Cell Mobilization of CD34+ Cells with Combine G-CSF and GM-CSF in Pediatric Patient Outcome and Economic Advantage." Blood 136, Supplement 1 (2020): 22. http://dx.doi.org/10.1182/blood-2020-136758.

Full text

Abstract:

Background: Clinical trials to mobilize PBPC for autologous and allogeneic harvesting prior to high dose chemotherapy/radiotherapy include chemotherapy, cytokines, or chemotherapy combine with cytokines. PBPC mobilized by G-CSF or GM-CSF reduces the hematological toxicity and supportive care requirements in recipients of autologous and allogeneic transplants, in our study we combined G-CSF and GM-CSF to mobilize PBPC for transplantation. Methods: We selected 63 patients with different cancers to participate in the study and 7 healthy donors. We utilize to mobilize in all the patient the combin

APA, Harvard, Vancouver, ISO, and other styles

16

Semochkin, S. V., V. V. Lunin, I. B. Kaplanskaya, and A. A. Fedenko. "Cyclosporine combined with eltrombopag for treatment of secondary graft failure after autologous hematopoietic stem cell transplantation." Oncohematology 19, no. 3 (2024): 132–41. http://dx.doi.org/10.17650/1818-8346-2024-19-3-132-141.

Full text

Abstract:

Graft failure (GF) is an extremely rare complication of autologous hematopoietic stem cell transplantation (auto-HSCT) with a frequency not exceeding 3–5 % of all cases of this technology. Primary graft failure is distinguished when restoration of hematopoiesis has not occurred by day +28 after hematopoietic stem cell transfusion, and secondary GF, implying the occurrence of neutropenia <0.5 × 109 /L after successful initial engraftment, which cannot be explained by tumor relapse, infections or chemotherapy toxicity.In this report, we present a clinical case of a 57-year-old woman with newl

APA, Harvard, Vancouver, ISO, and other styles

17

Šponer, Pavel, Tomáš Kučera, Jindra Brtková, et al. "Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects." Cell Transplantation 27, no. 10 (2018): 1459–68. http://dx.doi.org/10.1177/0963689718794918.

Full text

Abstract:

This prospective study sought to evaluate the healing quality of implanted ultraporous β-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received β-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received β-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts

APA, Harvard, Vancouver, ISO, and other styles

18

Castaño, C., C. Cubells, S. Remollo, MR García-Sort, and M. Terceño. "Use of a complete autologous blood recovery system (the Sorin Xtra® Autotransfusion System) during mechanical thrombectomy of extensive cerebral venous sinus thrombosis." Interventional Neuroradiology 23, no. 5 (2017): 531–37. http://dx.doi.org/10.1177/1591019917720908.

Full text

Abstract:

Background The endovascular therapy for cerebral venous sinus thrombosis (CVST) is currently accepted as a second-line treatment for patients who have failed or those in whom systemic anticoagulation is contraindicated or in a subgroup of patients presenting with rapid neurologic deterioration. A number of different mechanical and pharmacologic endovascular strategies have been reported, either as separate or combined approaches. These new catheters and aspiration systems have a high power and vacuum capacity, which carries a risk of anemization of the patient and hypovolemic shock, being nece

APA, Harvard, Vancouver, ISO, and other styles

19

Gratwohl, Alois, Helen Baldomero, Bruno Horisberger, Caroline Schmid, Jakob Passweg, and Alvaro Urbano-Ispizua. "Current trends in hematopoietic stem cell transplantation in Europe." Blood 100, no. 7 (2002): 2374–86. http://dx.doi.org/10.1182/blood-2002-03-0675.

Full text

Abstract:

Major changes have occurred in the transplantation of hematopoietic stem cells (HSCs) during the last decade. This report reveals the changes, reflects current status, and provides medium-term projections of HSC transplantation (HSCT) development in Europe. Data on 132 963 patients, 44 165 with allogeneic HSC transplant (33%) and 88 798 with an autologous HSC transplant (67%), collected prospectively from 619 centers by the European Group for Blood and Marrow Transplantation (EBMT) in 35 European countries between 1990 (4234 HSCTs) and 2000 (19 136 HSCTs) illustrate utilization of HSCT. HSCT i

APA, Harvard, Vancouver, ISO, and other styles

20

Gao, Liang, Patrick Orth, Magali Cucchiarini, and Henning Madry. "Autologous Matrix-Induced Chondrogenesis: A Systematic Review of the Clinical Evidence." American Journal of Sports Medicine 47, no. 1 (2017): 222–31. http://dx.doi.org/10.1177/0363546517740575.

Full text

Abstract:

Background: The addition of a type I/III collagen membrane in cartilage defects treated with microfracture has been advocated for cartilage repair, termed “autologous matrix-induced chondrogenesis” (AMIC). Purpose: To examine the current clinical evidence regarding AMIC for focal chondral defects. Study Design: Systematic review. Methods: A systematic review was performed by searching PubMed, ScienceDirect, and Cochrane Library databases. Inclusion criteria were clinical studies of AMIC for articular cartilage repair, written in English. Relative data were extracted and critically analyzed. PR

APA, Harvard, Vancouver, ISO, and other styles

21

Seegobin, Karan, Muhamad Alhaj Moustafa, Umair Majeed, et al. "Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience." Blood 138, Supplement 1 (2021): 1452. http://dx.doi.org/10.1182/blood-2021-146408.

Full text

Abstract:

Abstract Introduction: Intravascular lymphoma (IVL) is an extra nodal non-Hodgkin lymphoma with tropism for vascular endothelium. It is characterized by growth of large cells within the lumen of small to medium sized blood vessels. Central nervous system (CNS) and skin are predominantly involved. This report represents a retrospective single-institution review of IVL. Methods: We identified patients (pts) with IVL evaluated at Mayo Clinic Cancer Center between January 2003 and December 2018. Demographic, clinical, radiologic, pathologic, and therapeutic data were extracted. Statistical analysi

APA, Harvard, Vancouver, ISO, and other styles

22

Dipalma, Gianna, Angelo Michele Inchingolo, Valeria Colonna, et al. "Autologous and Heterologous Minor and Major Bone Regeneration with Platelet-Derived Growth Factors." Journal of Functional Biomaterials 16, no. 1 (2025): 16. https://doi.org/10.3390/jfb16010016.

Full text

Abstract:

Aim: This review aims to explore the clinical applications, biological mechanisms, and potential benefits of concentrated growth factors (CGFs), autologous materials, and xenografts in bone regeneration, particularly in dental treatments such as alveolar ridge preservation, mandibular osteonecrosis, and peri-implantitis. Materials and Methods. A systematic literature search was conducted using databases like PubMed, Scopus, and Web of Science, with keywords such as “bone regeneration” and “CGF” from 2014 to 2024. Only English-language clinical studies involving human subjects were included. A

APA, Harvard, Vancouver, ISO, and other styles

23

Thier, Steffen, Florian Baumann, Christel Weiss, and Stefan Fickert. "Feasibility of arthroscopic autologous chondrocyte implantation in the hip using an injectable hydrogel." HIP International 28, no. 4 (2017): 442–49. http://dx.doi.org/10.5301/hipint.5000580.

Full text

Abstract:

Introduction: In the long term the treatment of articular cartilage defects of the hip has the most direct impact on the postoperative outcome and should diminish degenerative changes caused by different pathologies. The purpose of this prospective feasibility study is to describe technical aspects of arthroscopic, injectable autologous chondrocyte implantation in the hip and to report the short-term outcome. Methods: Full-thickness cartilage defects of 13 patients were treated arthroscopically with an injectable autologous chondrocyte transplantation product (Novocart Inject, Tetec) in a 2-st

APA, Harvard, Vancouver, ISO, and other styles

24

Lazarides, Tzilalis, Georgiadis, Georgopoulos, and Arvanitis. "Femorodistale Rekonstruktionen auf die A. tibialis anterior mit PTFE-Prothesen und Venencuff: Alternativen der Bypassführung." Vasa 32, no. 1 (2003): 22–25. http://dx.doi.org/10.1024/0301-1526.32.1.22.

Full text

Abstract:

Background: The anterior tibial is the less often used artery for distal anastomosis in infrapopliteal bypass with synthetic grafts; however, several investigators argue against even an attempt to use non-autologous material for such distal reconstructions. Only few studies report patency rates mixing-up popliteal below-knee and various crural bypasses. Patients and methods: Nineteen consecutive femoral-anterior tibial cuffed PTFE bypass grafts, either via the lateral (n = 15) or interosseous (n = 4) route, were inserted in a 10-years period. Results: The 1-year and 2-year primary patency rate

APA, Harvard, Vancouver, ISO, and other styles

25

Notter, M., WD Ludwig, S. Bremer, and E. Thiel. "Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells." Blood 82, no. 10 (1993): 3113–24. http://dx.doi.org/10.1182/blood.v82.10.3113.3113.

Full text

Abstract:

Abstract The potential of the CD3 monoclonal antibody (MoAb) OKT3 to selectively target lymphokine-activated killer (LAK) cells and T-cell clones in vitro against autologous tumor cells was studied using material from patients with acute leukemias (19 acute myeloid leukemias [AML], and 3 acute lymphoblastic leukemias [ALL]). Cytotoxicity mediated by patient LAK cells against AML blasts, but not against ALL cells and autologous Epstein-Barr virus-transformed B cells, was enhanced 1.5-fold to 9.3- fold by OKT3 in all AML patients studied. The following findings suggest that the major target mole

APA, Harvard, Vancouver, ISO, and other styles

26

Notter, M., WD Ludwig, S. Bremer, and E. Thiel. "Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells." Blood 82, no. 10 (1993): 3113–24. http://dx.doi.org/10.1182/blood.v82.10.3113.bloodjournal82103113.

Full text

Abstract:

The potential of the CD3 monoclonal antibody (MoAb) OKT3 to selectively target lymphokine-activated killer (LAK) cells and T-cell clones in vitro against autologous tumor cells was studied using material from patients with acute leukemias (19 acute myeloid leukemias [AML], and 3 acute lymphoblastic leukemias [ALL]). Cytotoxicity mediated by patient LAK cells against AML blasts, but not against ALL cells and autologous Epstein-Barr virus-transformed B cells, was enhanced 1.5-fold to 9.3- fold by OKT3 in all AML patients studied. The following findings suggest that the major target molecule on A

APA, Harvard, Vancouver, ISO, and other styles

27

Guo, Xutao, Yunxia Zhang, Haohao Lei, et al. "The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART." Blood 144, Supplement 1 (2024): 7249. https://doi.org/10.1182/blood-2024-201948.

Full text

Abstract:

Objectives: To evaluate the effectiveness of low-dose Decitabine in combination with autologous hematopoietic stem cell infusion for patients experiencing persistent pancytopenia after CD19-chimeric antigen receptor T (CAR-T) therapy. Methods: Data from two adult patients with relapsed DLBCL and ongoing pancytopenia following CD19-CART therapy were analyzed. Results: Both patients achieved hematopoietic reconstitution following treatment with low-dose Decitabine and autologous hematopoietic stem cell infusion. Secondary MDS was ruled out by bone marrow aspiration and biopsy, which revealed bon

APA, Harvard, Vancouver, ISO, and other styles

28

Filip, Charles, Michael Matzen, Ingegerd Aagenses, et al. "Speech and Magnetic Resonance Imaging Results following Autologous Fat Transplantation to the Velopharynx in Patients with Velopharyngeal Insufficiency." Cleft Palate-Craniofacial Journal 48, no. 6 (2011): 708–16. http://dx.doi.org/10.1597/09-161.

Full text

Abstract:

Objective To measure velopharyngeal closure with magnetic resonance imaging (MRI) and to evaluate speech when treating velopharyngeal insufficiency (VPI) with autologous fat transplantation to the velopharynx. Patients Nine patients were recruited. Six patients had undergone cleft palate repair and subsequently developed VPI. Three were noncleft patients of which one had developed VPI after nasopharyngeal cancer treatment; another patient had developed VPI after combined adenotonsillectomy, and a third patient had VPI of unknown etiology. Main outcome measure Preoperative and 1-year postoperat

APA, Harvard, Vancouver, ISO, and other styles

29

Fraser, Graeme, Don Healey, Juan Carlos Rodriguez-Lecompte, et al. "Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia." Blood 108, no. 11 (2006): 3720. http://dx.doi.org/10.1182/blood.v108.11.3720.3720.

Full text

Abstract:

Abstract BACKGROUND: B-cell chronic lymphocytic leukemia (CLL) is currently incurable with conventional chemotherapeutic approaches. The induction of specific anti-CLL immune responses in vitro using autologous tumour-antigen loaded dendritic cell (DC)-based approaches has been previously demonstrated. The aim of this study was to optimize and validate large-scale production of an autologous DC vaccine prior to initiation of a planned Phase I/II clinical trial for patients with previously treated CLL. STUDY DESIGN: Following informed consent, 8 patients with confirmed CLL had 11 leukapheresis

APA, Harvard, Vancouver, ISO, and other styles

30

Sokol, Kelsey, Ruben Rhoades, Benjamin E. Leiby, et al. "Comprehensive geriatric assessment prior to autologous stem cell transplant as a predictor of patient outcomes: A retrospective review." Journal of Clinical Oncology 37, no. 15_suppl (2019): e23023-e23023. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e23023.

Full text

Abstract:

e23023 Background: While autologous stem cell transplant (ASCT) has been shown to be safe and effective in the geriatric population, age alone is not a sufficient predictor of outcomes. Minimal data exists regarding the use of a comprehensive geriatric assessment (CGA) tool prior to ASCT as a predictor of patient outcomes. This study aims to assess our institution’s pre-ASCT CGA on its ability to predict transplant-related outcomes in the elderly. Methods: We retrospectively analyzed all patients age 65 years of age and older (n = 68) who received ASCT at Thomas Jefferson University Hospital b

APA, Harvard, Vancouver, ISO, and other styles

31

Almadani, Hamzah, Jocelyn Lu, Sara Bokhari, Christiane How-Volkman, and Philip S. Brazio. "Simultaneous Vascularized Lymph Node Transfer and Breast Reconstruction: A Systematic Review." Journal of Clinical Medicine 14, no. 5 (2025): 1694. https://doi.org/10.3390/jcm14051694.

Full text

Abstract:

Background/Objectives: Simultaneous vascularized lymph node transfer (VLNT) and breast reconstruction is a reconstructive option that potentially addresses two adverse consequences of breast cancer treatment in the same operation. This systematic review aims to analyze the quality of data and outcomes in the current literature. Methods: This systematic review was performed following PRISMA guidelines. A systematic search was conducted with Google Scholar and PubMed for studies with the simultaneous intervention of VLNT and breast reconstruction. The search terms were ((diep OR pap OR expander

APA, Harvard, Vancouver, ISO, and other styles

32

Xiu, Bing, Bing Li, Xinyu Zhu, et al. "Complete Remissions to PD-1 Blockade in Combination with Reduced-Dose ICE Chemotherapy in Two Cases of Relapsed or Refractory Classical Hodgkin Lymphoma with Bulky Lung Involvement after Failed PD-1 Blockade." Blood 138, Supplement 1 (2021): 4368. http://dx.doi.org/10.1182/blood-2021-147134.

Full text

Abstract:

Abstract Objective: To report 2 cases of relapsed or refractory classical Hodgkin lymphoma with bulky lung involvement who failed PD-1 blockade, obtained long-term complete remission after treatment with PD-1 blockade in combination with ICE chemotherapy, and provide an alternative regimen for this kind of patient. Methods: The clinical data of 2 patients suffering refractory or relapsed Hodgkin's lymphoma with bulky lung involvement who were resistant to PD-1 monoclonal antibody were collected, the treatment processes, efficacy and toxic side effects of the patients were summarized. Results:

APA, Harvard, Vancouver, ISO, and other styles

33

Fostier, Karel, Jurgen Corthals, Carlo Heirman, et al. "Immunomodulatory Drugs Restore Effector Cell Immune Functions In Myeloma Patients With Low Disease Burden After Autologous Stem Cell Transplantation." Blood 122, no. 21 (2013): 3214. http://dx.doi.org/10.1182/blood.v122.21.3214.3214.

Full text

Abstract:

Abstract The micro-environment in multiple myeloma (MM) is highly immunosuppressive with increased numbers of regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) favoring tumorcell survival and hampering immunotherapeutic strategies such as dendritic cell vaccination. Immunomodulatory drugs (IMiDs) are known to enhance T- and NK-cell function. In this study we evaluated the effects of low dose (0.5 microM) lenalidomide (Len) and pomalidomide (Pom) on the functionality of CD8+ and CD4+ T cells, MDSCs, Tregs and ex-vivo generated mononuclear derived dendritic cells (moDCs) ob

APA, Harvard, Vancouver, ISO, and other styles

34

Kahn, Steven A., Jeffrey E. Carter, Gabriel G. Gaweda, et al. "299 Donor Site Reduction with Combined Use of Bromelain Enzymatic Debridement and Autologous Skin Cell Suspension." Journal of Burn Care & Research 44, Supplement_2 (2023): S193—S194. http://dx.doi.org/10.1093/jbcr/irad045.274.

Full text

Abstract:

Abstract Introduction The conventional treatment for deep 2nd and 3rd degree burn injuries has been excision and grafting, which was first described approximately 80 years ago. New techniques and technology in the field of burn surgery that facilitate “minimally invasive” donor site reduction include bromelain enzymatic debridement and autologous skin cell sprays (ASCS). Each of these techniques independently have been shown to decrease the need of autografting and reduce the donor site size. However, the use of both methods together was not possible until recently. The authors hypothesize tha

APA, Harvard, Vancouver, ISO, and other styles

35

Gasteratos, Konstantinos, Antonios Morsi-Yeroyannis, Nikolaos Ch Vlachopoulos, Georgia-Alexandra Spyropoulou, Gabriel Del Corral, and Kongkrit Chaiyasate. "Microsurgical techniques in the treatment of breast cancer-related lymphedema: a systematic review of efficacy and patient outcomes." Breast Cancer 28, no. 5 (2021): 1002–15. http://dx.doi.org/10.1007/s12282-021-01274-5.

Full text

Abstract:

Abstract Introduction Secondary lymphedema is the abnormal collection of lymphatic fluid within subcutaneous structures. Patients with lymphedema suffer a low quality of life. In our study, we aim to provide a systematic review of the current data on patient outcomes regarding breast cancer-related lymphedema (BCRL), and the most prevalent reconstructive techniques. Methods A PubMed (MEDLINE) and Scopus literature search was performed in September 2020. Studies were screened based on inclusion/exclusion criteria. The protocol was registered at the International Prospective Register of Systemat

APA, Harvard, Vancouver, ISO, and other styles

36

Zhao, Bing, Tingjun Dai, Dandan Zhao, et al. "Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy." Neurology - Neuroimmunology Neuroinflammation 9, no. 4 (2022): e1184. http://dx.doi.org/10.1212/nxi.0000000000001184.

Full text

Abstract:

Background and ObjectivesSporadic late-onset nemaline myopathy (SLONM) is a treatable or otherwise fatal myopathy. Diagnosis of SLONM is still challenging, and no therapeutic consensus has been achieved. Here, we reported the clinicopathologic features and long-term follow-up data of SLONM in a Chinese cohort.MethodsWe performed a retrospective evaluation of clinical, pathologic, and treatment outcomes of 17 patients with SLONM diagnosed between March 1986 and April 2021 at our neuromuscular center. Immunohistochemistry (IHC) with antibodies against 5 Z-disc–associated proteins was performed i

APA, Harvard, Vancouver, ISO, and other styles

37

Bruno, Tullia Carmela, Peggy Ebner, Brandon Moore, et al. "Antigen-presenting tumor B cells impact the phenotype of CD4 tumor infiltrating T cells in lung cancer patients." Journal of Immunology 198, no. 1_Supplement (2017): 130.26. http://dx.doi.org/10.4049/jimmunol.198.supp.130.26.

Full text

Abstract:

Abstract The focus of immunotherapy has been on CD8 and CD4 tumor infiltrating lymphocytes (TILs), however, tumor infiltrating B cells (TIL-Bs) are understudied with no focus on their role as antigen presenting cells. We hypothesize that TIL-Bs help generate potent, long-term immune responses against cancer by presenting tumor antigens to CD4 TILs. Using un-manipulated, primary human B cells from fresh tumor, we generated a specific in vitro antigen presentation assay and observed three types of CD4 TIL responses when TIL-Bs presented autologous tumor antigens. There were activated responder C

APA, Harvard, Vancouver, ISO, and other styles

38

Hofmeister, Craig C., Mindy A. Bowers, Yvonne A. Efebera, et al. "Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma." Blood 120, no. 21 (2012): 3114. http://dx.doi.org/10.1182/blood.v120.21.3114.3114.

Full text

Abstract:

Abstract Abstract 3114 Introduction: Post autologous transplant maintenance therapy for patients with multiple myeloma (MM) is standard of care (McCarthy et al, NEJM, 2012). Vorinostat (SAHA, Zolinza) is a HDAC inhibitor for which preclinical evidence suggests that its combination with bortezomib is synergistic via HDAC-6. Preclinical data suggests that HDAC-I's increase MHC class I and class II expression, rendering tumor cells more susceptible to host innate immune killing. Lenalidomide activates NK cells via PP2A inhibition and induces CD56 expression in CD16+CD56- cells thereby enhancing N

APA, Harvard, Vancouver, ISO, and other styles

39

Alegre, Adrian, Beatriz Aguado, M. Perez Alfonso, et al. "Laser Transmyocardial Revascularization (TMLR) Combined with Autologous Bone Marrow Cells (ABMC) for Diffuse Coronary Disease (DCD). Results In 19 Cases." Blood 116, no. 21 (2010): 1181. http://dx.doi.org/10.1182/blood.v116.21.1181.1181.

Full text

Abstract:

Abstract Abstract 1181 Introduction: Stem cells (SC) show a potential of cellular therapy in diffuse coronary disease with controverted results. We present here an analysis of a group of patients treated with TMLR plus ABMC. (Caiber Program Advanced Therapy Proyect FIS 2009). Patients and methods: 19 patients with DCD were included. Age 66 (range: 52–78). ABMC were obtained by aspiration and processed using HARVEST-TM system -TALEX (Harvest Technologies Inc. GMBH, Munich) to obtain 20 ml. Surgery consisted of anterior thoracotomy incision at the fourth and fifth intercostal space. Between 15–3

APA, Harvard, Vancouver, ISO, and other styles

40

Martinez Flores, Danaë, Dilara Akhoundova, Katja Seipel, et al. "Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia." Biomedicines 12, no. 7 (2024): 1616. http://dx.doi.org/10.3390/biomedicines12071616.

Full text

Abstract:

Gemtuzumab ozogamicin (GO), a CD33-targeting antibody drug conjugate, previously showed longer relapse-free survival when combined with induction chemotherapy in patients with favorable-risk acute myeloid leukemia (AML). In this patient population, characterized by lower relapse risk as compared to other ELN risk groups, autologous stem cell transplantation (ASCT) can be used as consolidation strategy. However, there are limited data on the impact of GO on the peripheral blood stem cell (PBSC) mobilization potential. We therefore retrospectively analyzed data from 54 AML patients with favorabl

APA, Harvard, Vancouver, ISO, and other styles

41

Abbi, Kamal Kant Singh, Sonya Behrends, Margarida Silverman, Umar Farooq, Kalyan Nadiminti, and Guido J. Tricot. "Salvage Tandem Autologous Stem Cell Transplant with Consolidation for Relapsed Multiple Myeloma." Blood 126, no. 23 (2015): 5497. http://dx.doi.org/10.1182/blood.v126.23.5497.5497.

Full text

Abstract:

Abstract Background: Therapeutic options for patients with Multiple myeloma (MM) whose disease has relapsed after a prior autologous stem cell transplant (SCT) include an expanding armamentarium of novel agents, often combined with traditional chemotherapy, or a second SCT, with no clear standard of care. Upfront tandem transplantation has been shown to improve both progression free survival and overall survival. But currently, there is little data regarding the application of tandem SCT in relapsed multiple myeloma patients. Methods: We retrospectively analyzed the outcomes of patients who un

APA, Harvard, Vancouver, ISO, and other styles

42

Romics jr., László, Sheila Stallard, and Eva Weiler-Mithoff. "Oncologic safety of skin-sparing mastectomy followed by immediate breast reconstruction: rate and localization of recurrences, and impact of reconstruction techniques." Orvosi Hetilap 154, no. 5 (2013): 163–71. http://dx.doi.org/10.1556/oh.2013.29529.

Full text

Abstract:

Introduction: Oncological safety of skin-sparing mastectomy followed by immediate breast reconstruction is widely debated. Current evidence is relatively poor since it is based mostly on short-term follow-up data of highly selected patient populations. Aim: Recurrence rates of a large cohort of non-selected patients, i. e. “all-comers” were analyzed during a 10-year follow up. Methods: Patient records and follow-up data of 253 consecutive cases treated with of skin-sparing mastectomy and immediate breast reconstruction between 1995 and 2000 were studied. During this time period “all-comers” po

APA, Harvard, Vancouver, ISO, and other styles

43

Mhibik, Maissa, Erika M. Gaglione, Amy Blackburn, et al. "A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib." Blood 134, Supplement_1 (2019): 2861. http://dx.doi.org/10.1182/blood-2019-126186.

Full text

Abstract:

Targeting B-cell receptor signaling with ibrutinib, the first-in-class irreversible inhibitor of Bruton tyrosine kinase, has become a highly successful treatment modality for Chronic Lymphocytic Leukemia (CLL) patients. However, there remains a need for adjunct treatments to deepen responses and prevent or treat resistant disease. Ibrutinib also inhibits inducible T-cell kinase (ITK) which is hypothesized to improve antitumor T-cell immunity. We developed a CD19/CD3 bispecific antibody (bsAb) in a 100 kDa single chain-Fv-Fc format (19/3-scFv-Fc). We previously reported increased T-cell activat

APA, Harvard, Vancouver, ISO, and other styles

44

Liu, Chenfei, Yuanbin Song, Yang Liang, Lu Lu, Weida Wang, and Bingyi Wu. "Efficiency and Safety of Pegylated Filgrastim Combined with Plerixafor in Multiple Myeloma Autologous Hematopoietic Stem Cells Mobilization." Blood 144, Supplement 1 (2024): 7118. https://doi.org/10.1182/blood-2024-207526.

Full text

Abstract:

Background Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) is an important treatment for Multiple Myeloma (MM). Effective stem cell mobilization is essential for the success of Auto-HSCT. Method We conducted a single-center retrospective analysis to investigate the most effective and safe mobilization regimen by analyzing data from 123 MM patients who underwent mobilization at Sun Yat-sen University Cancer Center from January 1, 2021 to June 30, 2024. We collected age, gender, previous recurrence, monoclonal immunoglobulin type, express Kappa or Lambda light chain, previous radi

APA, Harvard, Vancouver, ISO, and other styles

45

Isola, Luis, Karen M. Banoff, and Sara S. Kim. "Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients." Blood 118, no. 21 (2011): 2075. http://dx.doi.org/10.1182/blood.v118.21.2075.2075.

Full text

Abstract:

Abstract Abstract 2075 The most commonly employed agent for upfront stem cell mobilization is granulocyte-colony-stimulating factor (G-CSF), which is associated with about 25% of unsuccessful mobilization. Plerixafor was granted FDA approval based on improved rate of successful mobilization as an upfront mobilizing agent. However, because of its cost, it is often reserved for patients who failed previous standard mobilization. This strategy can increase the number of apheresis and potentially delay treatment. This retrospective study, performed between January 2008 and April 2011, included 50

APA, Harvard, Vancouver, ISO, and other styles

46

Bodine, DM, T. Moritz, RE Donahue, et al. "Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells." Blood 82, no. 7 (1993): 1975–80. http://dx.doi.org/10.1182/blood.v82.7.1975.1975.

Full text

Abstract:

Abstract Retroviral mediated gene transfer into stem cells has been proposed as therapy for many inherited hematopoietic diseases. Deficiency of the enzyme adenosine deaminase (ADA) results in depletion of T lymphocytes, causing severe combined immunodeficiency syndrome (SCIDS). In this report, we describe retroviral mediated gene transfer of a murine ADA cDNA into Rhesus monkey hematopoietic stem cells. Immunoselected CD34+ bone marrow cells were exposed to medium containing the ADA retrovirus during culture on a stromal cell line engineered to express the transmembrane form of stem cell fact

APA, Harvard, Vancouver, ISO, and other styles

47

Bodine, DM, T. Moritz, RE Donahue, et al. "Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells." Blood 82, no. 7 (1993): 1975–80. http://dx.doi.org/10.1182/blood.v82.7.1975.bloodjournal8271975.

Full text

Abstract:

Retroviral mediated gene transfer into stem cells has been proposed as therapy for many inherited hematopoietic diseases. Deficiency of the enzyme adenosine deaminase (ADA) results in depletion of T lymphocytes, causing severe combined immunodeficiency syndrome (SCIDS). In this report, we describe retroviral mediated gene transfer of a murine ADA cDNA into Rhesus monkey hematopoietic stem cells. Immunoselected CD34+ bone marrow cells were exposed to medium containing the ADA retrovirus during culture on a stromal cell line engineered to express the transmembrane form of stem cell factor. After

APA, Harvard, Vancouver, ISO, and other styles

48

Mattour, Ahmad Hatem, Shatha Farhan, Nalini Janakiraman, and Edward Peres. "Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant." Blood 124, no. 21 (2014): 5862. http://dx.doi.org/10.1182/blood.v124.21.5862.5862.

Full text

Abstract:

Abstract Background High dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) is considered the standard of care for patients with multiple myeloma (MM). With most patients receiving induction therapy that includes corticosteroids. The combined effect of prior therapy for myeloma and ASCT related complications may result in hypotension and require intensive medical treatment. To date the incidence of adrenal insufficiency in the setting of ASCT is unknown. The effects of this underlying disorder in regards to post transplant outcome remain unknown as well. We set out to c

APA, Harvard, Vancouver, ISO, and other styles

49

Sauerwein, RW, WG van der Meer, and LA Aarden. "Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma." Blood 70, no. 3 (1987): 670–75. http://dx.doi.org/10.1182/blood.v70.3.670.670.

Full text

Abstract:

Abstract Phorbol ester phorbol myristate acetate (PMA) induces proliferation in nonmalignant human B cells and B cells from a patient with B prolymphocytic leukemia (B-PLL). Mitogen-free T cell-derived conditioned medium acts synergistically with PMA in inducing proliferation of B-PLL cells but does not enhance the PMA-stimulated outgrowth of nonmalignant B cells. Interleukin 2 (IL-2) has no effect on the outgrowth of B-PLL cells, and monoclonal antibodies against the IL-2 receptor do not influence the response to PMA and conditioned medium. Recombinant interferon-gamma (IFN-gamma), in contras

APA, Harvard, Vancouver, ISO, and other styles

50

Sauerwein, RW, WG van der Meer, and LA Aarden. "Induction of proliferation of B prolymphocytic leukemia cells by phorbol ester and native or recombinant interferon-gamma." Blood 70, no. 3 (1987): 670–75. http://dx.doi.org/10.1182/blood.v70.3.670.bloodjournal703670.

Full text

Abstract:

Phorbol ester phorbol myristate acetate (PMA) induces proliferation in nonmalignant human B cells and B cells from a patient with B prolymphocytic leukemia (B-PLL). Mitogen-free T cell-derived conditioned medium acts synergistically with PMA in inducing proliferation of B-PLL cells but does not enhance the PMA-stimulated outgrowth of nonmalignant B cells. Interleukin 2 (IL-2) has no effect on the outgrowth of B-PLL cells, and monoclonal antibodies against the IL-2 receptor do not influence the response to PMA and conditioned medium. Recombinant interferon-gamma (IFN-gamma), in contrast, is a p

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!